INDIGO Biosciences launches IL-6R reporter assay for drug discovery

INDIGO Biosciences has launched a Human Interleukin-6 Receptor reporter assay designed to help researchers measure IL-6R signaling in inflammation, immunology, oncology and fibrosis studies. The ready-to-use kit is aimed at speeding functional screening and reducing internal assay development work for biopharma teams.

Why it matters: - IL-6R signaling is a high-value target in inflammation, autoimmune disease, cytokine dysregulation, oncology and fibrosis research. - A standardized functional assay can help drug teams compare compounds, measure potency and evaluate whether candidates activate or inhibit receptor signaling. - The launch gives researchers another off-the-shelf option for moving IL-6R testing into existing discovery workflows.

What happened: - INDIGO Biosciences launched its Human Interleukin-6 Receptor (IL-6R) Reporter Assay. - The company announced the product on Sept. 17, 2026, from State College, Pennsylvania. - The assay expands INDIGO Biosciences' cytokine receptor portfolio.

The details: - The assay is a cell-based reporter system that converts IL-6R activity into a quantitative luminescent readout. - The platform is designed for evaluating functional activation or inhibition of IL-6R signaling. - INDIGO says the assay supports candidate screening, potency comparison and functional characterization. - The kit is sold as an all-inclusive 96-well or 32-well format. - Each kit includes cryopreserved optimized reporter cells, media for cell recovery and compound dilution, a reference compound, luciferase detection reagents, a cell culture-ready assay plate and a detailed protocol. - The ready-to-use format is intended as an alternative to building and optimizing internal reporter cell lines and assays. - INDIGO also offers assay services for IL-6R studies, allowing customers to outsource screening to the company's scientific team.

Between the lines: - Functional assays add a layer beyond target-binding data by showing whether a candidate changes receptor signaling. - That distinction matters in IL-6R programs, where both small molecules and biologics may need functional validation before advancing. - The launch fits INDIGO Biosciences' broader push into clinically and commercially important drug targets.

What's next: - Researchers can use the Human IL-6R Reporter Assay Kit for screening and characterization studies. - INDIGO Biosciences is directing interested users to its website for product details and to its team for assay service discussions and screening requirements. - The company is likely to keep expanding its ready-to-use cell-based assay lineup as demand grows for faster functional testing.